• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Arno Andrew

    1/31/25 4:37:08 PM ET
    $VTAK
    Medical/Dental Instruments
    Health Care
    Get the next $VTAK alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Arno Andrew

    (Last) (First) (Middle)
    1670 HIGHWAY 160 WEST
    SUITE 205

    (Street)
    FORT MILL SC 29708

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Catheter Precision, Inc. [ VTAK ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    01/29/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option $0.42 01/29/2025 A 100,000 (1) 01/29/2035 Common stock 100,000 $0 100,000 D
    Explanation of Responses:
    1. 33.33% exercisable on January 29, 2025, 33.33% exercisable on January 29, 2026, and 33.34% exercisable on January 29, 2027.
    /s/ Andrew Arno 01/31/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $VTAK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VTAK

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VTAK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Anderson Philip J

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      3/3/25 5:17:48 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Director Colombatto Martin J sold $1 worth of shares (3 units at $0.40) (SEC Form 4)

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/31/25 4:39:51 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chairman of the Board and CEO Jenkins David A

      4 - Catheter Precision, Inc. (0001716621) (Issuer)

      1/31/25 4:39:10 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    Leadership Updates

    Live Leadership Updates

    See more
    • Catheter Precision, Inc. Announces New Chief Financial Officer

      FORT MILL, SC / ACCESSWIRE / January 7, 2025 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced that it has brought on board Philip Anderson, to take on the position of Chief Financial Officer. Margrit Thomassen, who has been our Interim Chief Financial Officer, will continue with the company in the role of Controller.David Jenkins, CEO of Catheter Precision, commented on the hire, "After some time of searching for the right fit, we are happy to have concluded our search with Phil Anderson joining the team. His background includes executive management across a variety of industries, managing hedge fund

      1/7/25 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. (NYSE American:VTAK) Presenting at the Sequire Investor Summit in Puerto Rico

      FORT MILL, SC / ACCESSWIRE / January 22, 2024 / Catheter Precision, Inc. (NYSE:VTAK), (the Company) a pioneering U.S. based medical device company committed to enhancing the well-being of patients with cardiac arrhythmias, is pleased to declare its participation in the forthcoming Sequire Investor Summit 2024. The eagerly awaited event, slated for January 23-25, 2024, at the Condado Vanderbilt Hotel in San Juan, Puerto Rico, is poised to provide a spectrum of compelling opportunities for funds, companies, and investors.Puerto Rico has become a hub for family offices, funds, and affluent investors, thanks to its advantageous tax benefits. It stands out as one of the rare locations globally wh

      1/22/24 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

      FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th

      5/14/25 4:30:00 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results

      FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.The number of hospitals, inclu

      3/28/25 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision Inc. Engages PCG Advisory to Broaden Investor Relations Strategy

      BRIDGEWATER, N.J., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Catheter Precision Inc. (NYSE:VTAK) ("Catheter Precision" or the "Company"), a U.S.-based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market, today announced its engagement with PCG Advisory, a leading investor relations, strategic communications, and digital strategies firm, to enhance investor outreach and communication efforts. By partnering with PCG Advisory, Catheter Precision seeks to strengthen its engagement with institutional and retail investors, effectively communicate its strategic vision, and increase market awareness of its LockeT and VIVO™ technologies—t

      2/10/25 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

      SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

      11/14/24 5:12:56 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Catheter Precision Inc.

      SC 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

      11/13/24 11:14:58 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Catheter Precision Inc.

      SC 13D/A - Catheter Precision, Inc. (0001716621) (Subject)

      10/30/24 5:26:20 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    Financials

    Live finance-specific insights

    See more
    • Catheter Precision, Inc. Announces First Quarter 2025 Update and Financial Results

      FORT MILL, S.C., May 14, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending March 31, 2025. Highlights of the first quarter include: Commercial Endeavors Approximately 50 hospitals are currently in the process of evaluating either VIVO, LockeT or both devices demonstrating that our new sales team continues to build a strong pipeline.After the close of the March quarter, the Company announced its acquisition of the assets of Cardionomics, Inc. through its newly formed, 82% owned subsidiary, Cardionomix, Inc. Th

      5/14/25 4:30:00 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. Announces Fourth Quarter and Full Year 2024 Update and Financial Results

      FORT MILL, S.C., March 28, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending December 31, 2024. Highlights of 2024 and the fourth quarter include: New Chief Commercial Officer (CCO) joined in Q2, 2024.Replaced the majority of our prior sales team with new salespeople selected by our new CCO and our CEO. Training was completed in Q3, 2024.The first sales of LockeT occurred in Q2 2024 and grew sequentially each quarter through the end of the year, to both new and repeat customers.The number of hospitals, inclu

      3/28/25 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision, Inc. Announces Third Quarter Update and Financial Results

      FORT MILL, SC / ACCESSWIRE / November 13, 2024 / Catheter Precision, Inc. (NYSE:VTAK), a U.S.-based innovative medical device company focused on electrophysiology products, today announced its financial results and operational update for the period ending September 30, 2024.Highlights of the third quarter include:Commercial EndeavorsMarie-Claude Jaques, our new Chief Commercial Officer, has now completed her first full quarter of engagement with the company, along with many of the new sales and clinical persons brought on board midway through the second quarter.The company now has 87 hospitals, including ambulatory surgical centers, in its pipeline of potential customers who have expressed i

      11/13/24 8:00:00 AM ET
      $VTAK
      Medical/Dental Instruments
      Health Care

    $VTAK
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Catheter Precision Inc.

      SCHEDULE 13G/A - Catheter Precision, Inc. (0001716621) (Subject)

      5/15/25 3:21:49 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Catheter Precision Inc.

      10-Q - Catheter Precision, Inc. (0001716621) (Filer)

      5/14/25 4:16:34 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care
    • Catheter Precision Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Catheter Precision, Inc. (0001716621) (Filer)

      5/8/25 4:06:25 PM ET
      $VTAK
      Medical/Dental Instruments
      Health Care